In the present study, MYH9 was expressed in 102 of 266 (38.3%) NSCLCs, and its expression was significantly correlated with an adenocarcinoma histology, poorer differentiation, and intratumoral vascular and lymphatic invasion. This evidence concerns the gene MYH9 and adenocarcinoma.